A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer

被引：5

作者：

Aono, Nana ^{[1
]}

Ito, Yuri ^{[2
,3
]}

Nishino, Kazumi ^{[3
]}

Uchida, Junji ^{[3
]}

Kumagai, Toru ^{[3
]}

Akazawa, Yuki ^{[3
]}

Okuyama, Takako ^{[3
]}

Yoshinami, Tetsuhiro ^{[1
]}

Imamura, Fumio ^{[3
]}

机构：

[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Med Oncol, Osaka 5378511, Japan

[2] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Canc Epidemiol & Prevent, Osaka 5378511, Japan

[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Osaka 5378511, Japan

来源：

CHEMOTHERAPY | 2012年 / 58卷 / 06期

关键词：

Non-small cell lung cancer; Chemotherapy; Paclitaxel; S1; Multivariate analysis; Shared frailty Cox model; RANDOMIZED PHASE-III; ANTITUMOR-ACTIVITY; PLUS PACLITAXEL; S-1; 5-FLUOROURACIL; CHEMOTHERAPY; RECURRENT; TRIAL; GEMCITABINE; CARBOPLATIN;

D O I：

10.1159/000345624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Recently, multiple-line chemotherapy has become popular for non-small cell lung cancer (NSCLC). The survival time of patients is influenced by patient characteristics and subsequent treatments. Methods: The usefulness of paclitaxel plus Si (PTX+S1) was evaluated in 46 pretreated NSCLC patients. Time from the start of individual regimens till the start of the next one (TNR) was calculated for regimens administered to the study population including PTX+S1 and analyzed by the shared frailty Cox model. Results: The response rate and the median progression-free survival time of PTX+S1 were 32.6% and 253 days, respectively. Substantial difference in TNR was observed in epidermal growth factor receptor mutation status and in line and type of regimens, but not in stage, age, sex, performance status and histology, by univariate analysis. Multivariate analysis revealed that PTX+S1 was only one factor to prolong TNR. Conclusion: Because of long progression-free survival and long TNR, further evaluation of PTX+S1 is necessary. Copyright (C) 2013 S. Karger AG, Basel

引用

页码：454 / 460

页数：7

共 22 条

[1] Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer [J].

Chelis, L. ;

Xenidis, N. ;

Amarantidis, K. ;

Prassopoulos, P. ;

Chamalidou, E. ;

Neanidis, K. ;

Mikroulis, D. ;

Chatzaki, E. ;

Karakitsos, P. ;

Kakolyris, S. .

CHEMOTHERAPY, 2010, 56 (05) :353-358

[2] EFFECTS OF THE PLASMA-CONCENTRATION OF 5-FLUOROURACIL AND THE DURATION OF CONTINUOUS VENOUS INFUSION OF 5-FLUOROURACIL WITH AN INHIBITOR OF 5-FLUOROURACIL DEGRADATION ON YOSHIDA SARCOMAS IN RATS [J].

FUJII, S ;

SHIMAMOTO, Y ;

OHSHIMO, H ;

IMAOKA, T ;

MOTOYAMA, M ;

FUKUSHIMA, M ;

SHIRASAKA, T .

JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (02) :167-172

[3] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[4] Effect of S-1 Adjuvant Chemotherapy on Survival following Recurrence and Efficacy of First-Line Treatment in Recurrent Gastric Cancer [J].

Hasegawa, Hiroko ;

Fujitani, Kazumasa ;

Kurokawa, Yukinori ;

Hirao, Motohiro ;

Nakazuru, Shoichi ;

Mita, Eiji ;

Tsujinaka, Toshimasa .

CHEMOTHERAPY, 2010, 56 (06) :436-443

[5]

HEGGIE GD, 1987, CANCER RES, V47, P2203

[6]

Kato T, 2001, ANTICANCER RES, V21, P1705

[7] Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer [J].

Kawahara, M ;

Furuse, K ;

Segawa, Y ;

Yoshimori, K ;

Matsui, K ;

Kudoh, S ;

Hasegawa, K ;

Niitani, H .

BRITISH JOURNAL OF CANCER, 2001, 85 (07) :939-943

[8]

Kogashiwa Y, 2008, CHEMOTHERAPY, V54, P479

[9] A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer [J].

Nakajo, Akihiro ;

Hokita, Shuichi ;

Ishigami, Sumiya ;

Miyazono, Futoshi ;

Etoh, Tadaaki ;

Hamanoue, Masahiro ;

Maenohara, Shigeho ;

Iwashita, Toshimitsu ;

Komatsu, Hideaki ;

Satoh, Kiyoharu ;

Aridome, Kuniaki ;

Morita, Satoshi ;

Natsugoe, Shoji ;

Takiuchi, Hiroya ;

Nakano, Shyuji ;

Maehara, Yoshihiko ;

Sakamoto, Junichi ;

Aikou, Takashi ;

Taxol, Kyushu .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) :1103-1109

[10] Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer [J].

Oh, Sung Yong ;

Lee, Gyeong-Won ;

Kim, Hoon Gu ;

Kim, Tae Hyo ;

Kim, Hyun Jin ;

Kang, Jung Hun .

CHEMOTHERAPY, 2008, 54 (06) :479-484

← 1 2 3 →